GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Stock Based Compensation

UPB (Upstream Bio) Stock Based Compensation : $8.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Stock Based Compensation?

Upstream Bio's Stock Based Compensation for the three months ended in Mar. 2025 was $2.64 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was $8.00 Mil.


Upstream Bio Stock Based Compensation Historical Data

The historical data trend for Upstream Bio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Stock Based Compensation Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24
Stock Based Compensation
1.28 3.43 6.00

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial 0.64 1.41 1.86 2.09 2.64

Upstream Bio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.00 Mil.


Upstream Bio Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Upstream Bio Business Description

Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.